| |
3001 ApoE ε4 carrier study
|
3000 ApoE ε4 noncarrier study
|
|---|
| |
PBO (n = 215)
|
BAP 0.5 (n = 275)
|
PBO (n = 76)
|
BAP 0.5 (n = 66)
|
BAP 1.0 (n = 56)
|
|---|
|
Mean age (years)
|
69.8
|
70.6
|
67.3
|
69.8
|
68.9
|
|
Femalea (%)
|
62.3
|
67.6
|
61.8
|
53.0
|
62.5
|
|
Whitea (%)
|
80.9
|
75.3
|
78.9
|
74.2
|
66.1
|
|
Asian (%)
|
18.1
|
22.9
|
21.1
|
25.8
|
32.1
|
|
Mean duration of AD (years)
|
2.89
|
2.98
|
2.73
|
2.85
|
2.87
|
|
Mean baseline MMSE
|
21.3
|
21.4
|
20.2
|
20.8
|
20.6
|
|
Current AChEI and/or memantine use, n (%)
|
|
Yes
|
199 (92.6)
|
255 (92.7)
|
70 (92.1)
|
56 (84.8)
|
54 (96.4)
|
|
No
|
16 (7.4)
|
20 (7.3)
|
6 (7.9)
|
10 (15.2)
|
2 (3.6)
|
|
ApoE ε4 allele count, n (%)
|
|
1
|
171 (79.5)
|
217 (78.9)
|
NA
|
NA
|
NA
|
|
2
|
44 (20.5)
|
58 (21.1)
|
NA
|
NA
|
NA
|
-
AChEI acetylcholinesterase inhibitor, AD Alzheimer’s disease, ApoE apolipoprotein E, BAP bapineuzumab, MMSE Mini-Mental State Examination, NA not applicable, PBO placebo
-
aA few patients may have been misclassified at baseline, causing discrepancy with Table 3: one patient was classified as male at parent baseline and female at extension baseline; three patients were classified as white at parent baseline and Asian or “other” at extension baseline
